Bill > SCR100

This Concurrent Resolution directs the Department of Health to establish a Therapeutic Psilocybin Working Group to investigate the potential medical and therapeutic benefits of psilocybin, a naturally occurring compound found in certain mushrooms that affects brain receptors and has shown promise in studies for treating conditions like depression and anxiety. The working group will examine existing laws and research on psilocybin's safety and effectiveness, and if the Food and Drug Administration (FDA), the federal agency responsible for approving medications, grants approval for psilocybin's medical use, the group will then create a comprehensive plan to ensure that psilocybin-based treatments are readily available, safe, and affordable for adults aged 21 and older. The resolution also specifies the members of this working group, including the Director of Health, the Attorney General, and representatives from medical and legislative bodies, and requires them to submit reports of their findings and recommendations to the Legislature.